title: Selective eosinophil leukocyte recruitment by transendothelial migration and not by leukocyte-endothelial cell adhesion.
abstract: Eosinophil infiltration is the hallmark of allergic inflammatory events. However, the mechanisms governing the influx of eosinophils into the tissue at a site of an allergic reaction remains unclear. We have examined the interactions of eosinophils and neutrophils isolated from the same atopic donor with cultured human umbilical vein endothelial cell (EC) monolayers in the search for a mechanism for this selective eosinophil recruitment. First, the adherence of eosinophils and neutrophils to ECs stimulated with lipopolysaccharide, interleukin (IL)-1 alpha, and tumor necrosis factor-alpha were compared. Each mediator induced a similar dose-dependent enhancement of eosinophil adhesiveness for both eosinophils and neutrophils. Thus, although cytokine activation of ECs in the vasculature adjacent to an inflammatory site probably serves as an important focusing mechanism for the extravasation of inflammatory cells at this site, there does not appear to be any selective EC-dependent mechanism for eosinophil recruitment. Little or no effect on eosinophil and neutrophil adherence was observed with IL-3, IL-5, granulocyte/macrophage colony-stimulating factor, platelet-activating factor (PAF), leukotriene B4, or histamine. Second, the migration of eosinophils and neutrophils through an EC monolayer in response to chemoattractants was examined. PAF was found to selectively enhance eosinophil transendothelial migration at doses of 10(-7) to 10(-10) M, with optimal effect at 10(-8) M. This effect was gradient dependent and could be inhibited by WEB 2086, a specific PAF inhibitor. These results suggest that localized production of PAF may be a prime factor in the events leading to eosinophil accumulation at allergic inflammatory sites, and that selectivity for eosinophil recruitment occurs at the stage of transendothelial cell migration under the influence of cell-specific chemoattractants.
authors.affiliation: Department of Pathology, University of Southampton, United Kingdom.
authors.forename: C M
authors.initials: CM
authors.lastname: Morland
authors.forename: S J
authors.initials: SJ
authors.lastname: Wilson
authors.forename: S T
authors.initials: ST
authors.lastname: Holgate
authors.forename: W R
authors.initials: WR
authors.lastname: Roche
mesh_terms: D000640:Amitrole / Q000494:pharmacology; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement; D016207:Cytokines / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology*; D004804:Eosinophils / Q000166:cytology / Q000502:physiology*; D006801:Humans; D006967:Hypersensitivity / Q000503:physiopathology; D066298:In Vitro Techniques; D007375:Interleukin-1 / Q000494:pharmacology; D007975:Leukotriene B4 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008854:Microscopy, Electron; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000166:cytology / Q000502:physiology*; D010544:Peroxidases / Q000037:antagonists & inhibitors / Q000378:metabolism; D010972:Platelet Activating Factor / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D016207:Cytokines; D007375:Interleukin-1; D008070:Lipopolysaccharides; D010972:Platelet Activating Factor; D014409:Tumor Necrosis Factor-alpha; D007975:Leukotriene B4; D009240:N-Formylmethionine Leucyl-Phenylalanine; D010544:Peroxidases; D000640:Amitrole